GlassScriptPhysician profile
An L Tran
NPI 1366637563
$7,507.36
in general payments reported to CMS, 2019-2025
59 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,305 · 2020: $486 · 2021: $23.16 · 2022: $156 · 2023: $1,518 · 2024: $1,435 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,517 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,516.99 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $730.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $499.65 | 2019-2024 | Keytruda |
| Pfizer INC. | $341.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.06 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $279.04 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Takeda Pharmaceuticals U.S.A., INC. | $263.25 | 2019-2025 | Ninlaro, Fruzaqla |
| Lilly USA, LLC | $248.57 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $247.55 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $245.44 | 2020-2025 | Enhertu |
| Amgen INC. | $245.03 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Celgene Corporation | $243.30 | 2019-2025 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $230.05 | 2019-2025 | Libtayo |
| Genentech USA, INC. | $228.20 | 2019 | |
| Tersera Therapeutics LLC | $223.45 | 2019-2025 | Zoladex, Xermelo |
| Exelixis INC. | $207.70 | 2019-2025 | Cabometyx |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $190.00 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Stemline Therapeutics INC. | $176.27 | 2023-2025 | Orserdu |
| Genzyme Corporation | $173.70 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.69 | 2019-2025 | |
| Abbvie INC. | $160.16 | 2020-2025 | |
| Mirati Therapeutics, INC. | $146.30 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $138.90 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Janssen Biotech, INC. | $135.50 | 2019-2024 | Darzalex, Tecvayli, Imbruvica |
| Astellas Pharma US INC | $113.32 | 2019-2024 | Xtandi |
| Kite Pharma, INC. | $110.77 | 2025 | Yescarta |
| Array Biopharma INC | $110.10 | 2019-2024 | Braftovi, Lorbrena, Mektovi |
| Eisai INC. | $108.17 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $101.55 | 2019-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $88.40 | 2023-2024 | |
| Beigene USA, INC. | $75.75 | 2023-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $65.28 | 2019-2024 | Rezlidhia, Tavalisse |
| Alexion Pharmaceuticals, INC. | $61.05 | 2024-2025 | Ultomiris |
| Lexicon Pharmaceuticals, INC. | $59.27 | 2019-2020 | |
| Seagen INC. | $58.17 | 2019-2023 | Tukysa |
| Genmab U.S., INC. | $54.69 | 2024-2025 | Epkinly |
| Sun Pharmaceutical Industries INC. | $46.85 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $46.01 | 2023-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $44.39 | 2019-2024 | Onivyde |
| Taiho Oncology, INC. | $43.44 | 2019-2025 | |
| Emd Serono, INC. | $43.42 | 2023-2024 | Bavencio |
| Sobi, INC | $37.87 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.41 | 2019-2025 | Gilotrif |
| Pharmacosmos Therapeutics INC. | $34.85 | 2025 | Monoferric |
| Aurobindo Pharma USA, INC. | $27.76 | 2019 | |
| Legend Biotech USA INC. | $27.68 | 2025 | Carvykti |
| Adc Therapeutics America, INC. | $25.91 | 2024 | |
| Foundation Medicine, INC. | $23.31 | 2019 | |
| Beone Medicines USA, INC. | $22.88 | 2025 | Tevimbra |
| Geron Corporation | $21.60 | 2025 | Rytelo |
| G1 Therapeutics, INC. | $21.05 | 2023 | Cosela |
| Biocompatibles, INC. | $19.81 | 2019 | |
| Portola Pharmaceuticals, LLC | $18.32 | 2019 | |
| Heron Therapeutics, INC. | $17.96 | 2019 | |
| Cti Biopharma Corp. | $17.71 | 2023 | Vonjo |
| Zimvie INC. | $16.10 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2019 | |
| Mylan Institutional INC. | $11.69 | 2019 | |
| Dova Pharmaceuticals | $11.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.